Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
1998-04-09
2001-08-21
Myers, Carla J. (Department: 1656)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S069100, C435S071100, C435S320100, C435S252300, C435S471000, C435S455000, C536S023500, C536S024310, C536S024330
Reexamination Certificate
active
06277568
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to nucleic acid and amino acid sequences of human ubiquitin-conjugating enzyme homologs and to the use of these sequences in the diagnosis, treatment, and prevention of cancer, autoimmune disorders, and neuronal disorders.
BACKGROUND OF THE INVENTION
The ubiquitin system is a major pathway for selective protein degradation. (Finley D. et al. (1991) Annu. Rev. Cell Biol. 7: 25-69.) Degradation by this system is instrumental in a variety of cellular functions such as DNA repair, cell cycle progression, signal transduction, transcription, and antigen presentation. The ubiquitin pathway also eliminates proteins that are misfolded, misplaced, or that are in other ways abnormal. This pathway requires the covalent attachment of ubiquitin (El), a highly conserved 76 amino acid protein, to defined lysine residues of substrate proteins.
Substrate recognition by this pathway involves a specialized recognition and targeting apparatus, known as the ubiquitin-conjugating system. Ubiquitin-conjugating enzyme (E2) and ubiquitin-protein ligase (E3), either independently or in conjunction, catalyze isopeptide formation between the carboxyl terminus of ubiquitin and amino groups of internal lysine residues of target proteins. (Scheffner M. et al. (1995) Nature 373: 81-83.) Ubiquitin-protein conjugates are then recognized and degraded by a specific protease complex, the 26S proteasome. Both E2 and E3 exist as protein families, and their pattern of expression is thought to determine substrate specificity. (Nuber U. et al. (1996) J. Biol. Chem. 271: 2795-2800.) For example, E6 oncoprotein of the cancer-associated human papillomavirus types 16 and 18, inactivates the tumor suppressor protein p53 via the ubiquitin protein degradation pathway. An E3 protein, E6-AP, and an E2 protein, either UbcH5 or UbcH7, complex with E6 and specifically conjugate ubiquitin to p53. (Scheffner M. et al. (1993) Cell 75: 495-505; Nuber et al., supra.) Other E2 proteins are not sufficient for p53 ubiquitination, thus UbcH5 and UbcH7 appear to be involved in the specific targeting of p53 for degradation.
The yeast ubiquitin-conjugating enzyme, Ubc3, also known as CDC34, plays a crucial role in the progression of the cell cycle from the G1 to S. Correct positioning of ubiquitin on a surface of Ubc3 is a requirement for cell cycle transition. (Prendergast J. A. et al. (1995) J. Biol. Chem. 270: 9347-9352.) Mutation studies have suggested that amino acid residues S73, S97, and S 139 of Ubc3 may be critical for substrate specificity, while C95 is the site of catalytic activity. (Liu Y. et al. (1995) Mol. Cell Biol. 15: 5635-5644.) An alteration in C95 and another highly conserved amino acid, L99, results in a dominant negative mutation. (Banerjee A. et al. (1995) J. Biol. Chem. 270: 26209-26215.) Overexpression of this mutation of Ubc3 blocks cell growth in otherwise wild type strains.
A decrease in muscle mass, known as muscle wasting or cachexia, has been shown to be associated with the ubiquitin-dependent proteolytic system. Rats bearing the Yoshida AH-130 ascites hepatoma for 7 days showed a significant decrease in muscle mass in relation to non-tumor bearing controls. (Llovera M. et al. (1995) Int. J. Cancer 61: 138-141.) The muscle wasting was found to be associated with an increased proteolytic rate related to the ubiquitin-dependent proteolytic system. Muscle wasting is common among human cancer patients. In addition to cancer, ubiquitin-dependent muscle wasting is also influenced by nutritional manipulation such as fasting and dietary protein deficiency, muscle activity and disuse, AIDS, and the pathological conditions, sepsis, trauma, and acidosis. (Attaix D. et al. (1994) Reprod. Nutr. Dev. 34: 583-597.) In a rat model for long lasting sepsis, researchers found that E2 mRNA levels increase during the acute and chronic disease phases and parallel a rise in muscle protein breakdown. (Voisin L. et al. (1996) J. Clin. Invest. 97: 1610-1617.)
Evidence from experiments on mouse and rabbit reticulocytes indicates that ubiquitin conjugation is a key rate-limiting step in antigen presentation. (Grant E. P. et al. (1995) J. Immunol. 155: 3750-3758.) The rates of degradation of beta-galactosidase constructs correlated with the rates of class I antigen presentation in vivo. This shows that ubiquitin degradation pathways may have a critical role in generating major histocompatibility complex (MHC) class I-presented peptides.
The presence of ubiquitin and ubiquitin conjugates has been detected in patients affected by neurodegenerative diseases such as Alzheimer's disease. Whereas the intracellular amyloid beta-protein precursor (APP) did not show appreciable ubiquitin- mediated degradation, three extracellular APP forms were degraded by this proteolytic pathway, suggesting a potential regulatory role for the ubiquitin-dependent system in the in vivo APP metabolic pathway. (Gregori L. et al. (1994) Biochem. Biophys. Res. Commun. 203: 1731-1738.) Paired helical filaments (PHF) are fibrillar structures that accumulate in degenerating neurons in the brains of Alzheimer's disease patients. One component of PHF, the PHF-smear, consists of the tau protein fragment bound to ubiquitin. (Morishima M. et al. (1994) Dementia 5: 282-288.)
Depletion of specific cellular proteins may have many medical and agricultural benefits. Redirecting the ubiquitin-dependent proteolytic pathway may facilitate specific proteolytic removal. Five exanples in which target recognition by E2s was redefined by engineering E2s to contain appropriate protein-binding peptides fused to their C termini have been reported. (Gosink M. M. et al. (1995) Proc. Natl. Acad. Sci. 92: 9117-9121.) Thus, it may be possible to design E2s capable of directing the selective removal of many intracellular proteins, such as those implicated in pathogenesis, for example in Alzheimer's disease. The ability to selectively modulate E2 activity may be useful for treating diseases associated with protein degradation, such as Alzheimer's disease, muscle wasting syndrome, or for targeting undesired proteins for degradation, such as in the case of viral infections and cancer.
The discovery of new human ubiquitin-conjugating enzyme homologs and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, treatment, and prevention of cancer, autoimmune disorders, and neuronal disorders.
SUMMARY OF THE INVENTION
The invention features substantially purified polypeptides, human ubiquitin-conjugating enzymes, referred to collectively as “UCEH” and individually as “UCEH-1,” “UCEH-2,” and “UCEH-3.” In one aspect, the invention provides a substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, a fragment of SEQ ID NO:1, a fragment of SEQ ID NO:2, and a fragment of SEQ ID NO:3.
The invention further provides a substantially purified variant having at least 90% amino acid identity to the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, or to a fragment of any of these sequences. The invention also provides an isolated and purified polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, a fragment of SEQ ID NO:1, a fragment of SEQ ID NO:2, and a fragment of SEQ ID NO:3. The invention also includes an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, a fragment of SEQ ID NO:1, a fragment of SEQ ID NO:2, and a fragment of SEQ ID NO:3.
Additionally, the invention provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ
Azimzai Yalda
Baughn Mariah
Corley Neil C.
Guegler Karl J.
Hillman Jennifer L.
Incyte Genomics Inc.
Incyte Genomics, Inc.
Myers Carla J.
LandOfFree
Nucleic acids encoding human ubiquitin-conjugating enzyme... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids encoding human ubiquitin-conjugating enzyme..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding human ubiquitin-conjugating enzyme... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2546989